UB-421 SC
/ United BioPharma
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
April 24, 2023
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients
(clinicaltrials.gov)
- P1 | N=15 | Completed | Sponsor: United BioPharma | Recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ May 2022 | Trial primary completion date: Dec 2023 ➔ May 2022
Trial completion • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4
May 13, 2022
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults
(clinicaltrials.gov)
- P1 | N=18 | Not yet recruiting | Sponsor: United BioPharma | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2025
Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4
May 10, 2021
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults
(clinicaltrials.gov)
- P1; N=18; Not yet recruiting; Sponsor: United BioPharma; Initiation date: Jan 2021 ➔ Dec 2021
Clinical • Trial initiation date • Human Immunodeficiency Virus • Infectious Disease • CD4
February 08, 2021
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients
(clinicaltrials.gov)
- P1; N=18; Recruiting; Sponsor: United BioPharma; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Human Immunodeficiency Virus • Infectious Disease • CD4
November 06, 2020
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients
(clinicaltrials.gov)
- P1; N=18; Not yet recruiting; Sponsor: United BioPharma
Clinical • New P1 trial • Human Immunodeficiency Virus • Infectious Disease
November 06, 2020
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults
(clinicaltrials.gov)
- P1; N=18; Not yet recruiting; Sponsor: United BioPharma
Clinical • New P1 trial • Human Immunodeficiency Virus • Infectious Disease
1 to 6
Of
6
Go to page
1